This is a topic that gets scant attention leaving the consuming public largely in the dark. Even though I work in the field, I’ve not hear this information except from my own reading. Fortunately, SSRIs are not as susceptible to problems crossing from brands to generics or between generics. But buproprion in other forms may not be as good as Wellbutrin. Image via Wikipedia Medical News “Antidepressant and antipsychotic drugs have become blockbusters for the firms that developed them, making them hot markets for generic competition.
There is an important new research study on treatment of schizophrenia. They have found delayed or interrupted treatment is associated with permanent lost brain function and less success in recovery. That is indeed my clinical experience with schizophrenia and bipolar disorder. Any kind of chronic brain dysfunction makes permanent changes to brain structures and functioning. PTSD has been associated with permenent changes in emotion intensity and increased difficulty in emotion regulation.
Anti-psychotic medication has gotten very expensive, especially when compared to long standing generics. Now research is finding the generics work just as well as the new “atypicals”. But the fact is, medication has to be subscribed one client at a time. While on average, some of the generics work as well with low side effects, some individuals have extreme side effects from the generics or don’t benefit from them any where near as effectively as the new “atypicals”.
Some of you might remember the report released last year saying that an older medication Trilafon was just as effective as the new MUCH more expensive medications. Even though NIMH commented later that the research did not support that belief, many Medicaid programs wrote the new medications out of their formularies. A follow-up to this research has reinforced the fact that most psychiatrists already know. Each person’s body chemistry responds uniquely to each medication.
NIMH has published a press release on initial results of an important new study of anti-psychotic medications. The study compares the newer medications with an older medication thought to have a lower incidence of movement disorders. NIMH: NIMH Study To Guide Treatment Choices for Schizophrenia In the CATIE (Clinical Antipsychotic Trials of Intervention Effectiveness) trial, researchers directly compared an older medication (perphenazine), available since the 1950s, to four newer medications (olanzapine, quetiapine, risperidone, and ziprasidone), introduced in the 1990s.
[Anti-psychotic drug warning for seniors with dementia] U.S. health officials Monday advised physicians not to give elderly patients with dementia anti-psychotic drugs approved for other medical conditions. The Food and Drug Administration said the drugs included in the warning were Abilify (aripiparozole), Zyprexa (olanzapine), Seroquel (quetiapine), Risperdal (risperidone), Clozaril (clozapine) and Geodon (ziprasidone). All are approved for treatment of schizophrenia and mania but are associated with a higher death rate when given to elderly patients with dementia for behavioral problems.
[Doctors should Monitor Metabolic Side Effects of Anti-Psychotics] Psychiatrists are doing a “modest” job of monitoring for weight gain, diabetes and other metabolic problems that may result from use of the newer antipsychotics for schizophrenia, researchers say. Nearly all of the 258 members of the American Psychiatric Association in Georgia, Ohio and Iowa responding to a survey said they considered metabolic side effects serious or very serious, said researchers from the Medical College of Georgia, University of Iowa and Northcoast Behavioral Healthcare in Ohio.